Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 21 peer-reviewed journal articles Updated
Dermatology

Monitoring and Multi-Organ Surveillance: A Proactive Plan

At a Glance

Individuals with familial melanoma require specialized, lifelong surveillance. Standard monitoring involves total body photography and digital dermoscopy every 6-12 months. Those with CDKN2A or BAP1 mutations need additional internal screenings for pancreatic, eye, and kidney cancers.

Living with a genetic predisposition to melanoma can feel like waiting for a storm, but a proactive surveillance plan is your most powerful tool. When we catch cancers early through these specialized screenings, they are significantly more treatable, and in many cases, this surveillance leads to improved survival [1][2].

Protecting Your Skin

For individuals with familial melanoma or mutations like CDKN2A, standard skin checks are not enough. Experts recommend a “two-step” approach to surveillance [3]:

  • Total Body Photography (TBP): High-resolution photographs of your entire skin surface serve as a baseline. At future visits, your doctor can compare your skin to these photos to spot new or changing moles that might otherwise be missed [3][4].
  • Sequential Digital Dermoscopy (SDDI): Your dermatologist uses a handheld magnifying tool (dermoscope) to take microscopic images of individual moles [1]. By tracking these images over time, doctors can identify subtle “biological” changes before a mole even looks suspicious to the naked eye [5][1].

Most adult high-risk patients are screened every 6 to 12 months, though your doctor may recommend more frequent checks if you have a very high mole count [6][7]. For children in families with a history of familial melanoma, baseline skin checks typically begin around age 10 to 12, or earlier if unusual moles are noticed or a high-penetrance gene is present in the family [1].

Protecting Your Pancreas (for CDKN2A carriers)

Because the CDKN2A mutation also affects the pancreas, specialized internal imaging is vital. While standard abdominal ultrasounds are often not sensitive enough, two specific tests are recommended [8][9]:

  1. MRI/MRCP: A non-invasive scan that uses magnetic fields to create detailed images of the pancreatic ducts [9][10].
  2. Endoscopic Ultrasound (EUS): A procedure where a thin tube with an ultrasound probe is passed down the throat while you are under anesthesia or heavy sedation. It is an outpatient procedure that typically takes less than an hour, allowing the doctor to get a very close, high-resolution look at the pancreas without surgery [8][11].

When to Start: Guidelines typically recommend starting these screenings at age 40 or 50, or 10 years earlier than the youngest pancreatic cancer diagnosis in your family [12][8]. These exams are usually repeated every 12 months [12].

Protecting the Eyes and Beyond (for BAP1 carriers)

The BAP1 mutation requires a broader “whole-body” approach to monitoring [13][14]:

  • Eye Exams: An annual dilated eye exam by an ophthalmologist (ideally one specializing in eye tumors) is essential to check for uveal melanoma [15][16]. Close monitoring of any small pigmented spots in the eye is necessary [17].
  • Kidney Imaging: Regular imaging (often via MRI or ultrasound) is used to screen for renal cell carcinoma [18][13].
  • Chest and Abdomen: Doctors monitor for signs of mesothelioma (cancer of the lining of the lungs or abdomen). This includes being alert for persistent coughs or shortness of breath [19][13].
  • Neurological Checks: Recent evidence suggests that brain and spinal imaging may be considered, as meningiomas can also be linked to BAP1 [20][21].

Summary of Surveillance

Organ Target Population Method Frequency
Skin All Familial Melanoma Total Body Photography + Dermoscopy [3] Every 6–12 months [6]
Pancreas CDKN2A Carriers MRI/MRCP or Endoscopic Ultrasound [9] Every 12 months [12]
Eyes BAP1 Carriers Dilated Ophthalmological Exam [15] Every 12 months [15]
Kidneys BAP1 Carriers Abdominal MRI or Ultrasound [18] As directed by specialist [13]

By following these protocols, you are not just watching for disease; you are taking an active role in ensuring that if anything does occur, it is caught at its most manageable stage.

Common questions in this guide

How often should I get skin checks if I have a family history of melanoma?
Most adults with a high risk for familial melanoma should have specialized skin exams every 6 to 12 months. Your dermatologist may recommend more frequent visits if you have a very high number of moles.
What is the difference between a regular skin check and total body photography?
Total body photography creates a high-resolution baseline map of your entire skin surface. This allows your dermatologist to compare current moles against past photos to spot subtle, new, or changing spots that a standard exam might miss.
At what age should pancreatic screening begin for CDKN2A mutation carriers?
Pancreatic screening usually begins at age 40 or 50, or 10 years earlier than the youngest pancreatic cancer diagnosis in your family. This is typically done annually using specialized MRI scans or an endoscopic ultrasound.
Why do I need an eye exam if I have a BAP1 mutation?
The BAP1 genetic mutation increases the risk of uveal melanoma, a type of eye cancer. An annual dilated eye exam by a specialized ophthalmologist is essential to monitor for any small pigmented spots in the eye.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.How often should I have full-body skin exams, and will my doctor be using both photography and digital dermoscopy?
  2. 2.Since I have a CDKN2A mutation, at what age should I begin my first pancreatic screening?
  3. 3.Which pancreatic imaging test (MRI/MRCP or EUS) do you recommend for me, and can these be done at this facility?
  4. 4.Can you refer me to an ophthalmologist who is familiar with BAP1-related eye monitoring?
  5. 5.What symptoms of mesothelioma or kidney cancer should I be monitoring for at home?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (21)
  1. 1

    Surveillance, CDKN2A and survival of familial melanoma.

    van Doorn R

    Journal of the European Academy of Dermatology and Venereology : JEADV 2023; (37(2)):218-219 doi:10.1111/jdv.18796.

    PMID: 36640377
  2. 2

    Solar Lentigines are Associated with Better Outcome in Cutaneous Melanoma.

    Marasigan V, Güvenç C, Oord JJ, et al.

    Acta dermato-venereologica 2019; (99(12)):1154-1159 doi:10.2340/00015555-3270.

    PMID: 31314121
  3. 3

    Hereditary melanoma: Update on syndromes and management: Genetics of familial atypical multiple mole melanoma syndrome.

    Soura E, Eliades PJ, Shannon K, et al.

    Journal of the American Academy of Dermatology 2016; (74(3)):395-407; quiz 408-10.

    PMID: 26892650
  4. 4

    Phenotypic and Dermoscopic Patterns of Familial Melanocytic Lesions: A Pilot Study in a Third-Level Center.

    Roccuzzo G, Giordano S, Granato T, et al.

    Cancers 2023; (15(15)) doi:10.3390/cancers15153772.

    PMID: 37568588
  5. 5

    Association of Patient Risk Factors and Frequency of Nevus-Associated Cutaneous Melanomas.

    Haenssle HA, Mograby N, Ngassa A, et al.

    JAMA dermatology 2016; (152(3)):291-8 doi:10.1001/jamadermatol.2015.3775.

    PMID: 26536613
  6. 6

    Diagnosis and treatment strategies for hereditary pancreatic cancer syndrome.

    Matsubayashi H, Morizane C, Kanai M, et al.

    International journal of clinical oncology 2025; doi:10.1007/s10147-025-02905-z.

    PMID: 41118024
  7. 7

    CDKN2A Mutation: A Patient's and Physician's Experience.

    Shaked Y, Swearingen A, Liebman TN

    Dermatology and therapy 2025; (15(2)):265-268 doi:10.1007/s13555-025-01354-w.

    PMID: 39921829
  8. 8

    The importance of a well-structured pancreatic screening program for familial and hereditary pancreatic cancer.

    Vasen HFA

    Familial cancer 2018; (17(1)):1-3 doi:10.1007/s10689-017-0066-y.

    PMID: 29204967
  9. 9

    Imaging for Screening/Surveillance of Pancreatic Cancer: A Glimpse of Hope.

    Elbanna KY, Jang HJ, Kim TK

    Korean journal of radiology 2023; (24(4)):271-273 doi:10.3348/kjr.2022.1035.

    PMID: 36907596
  10. 10

    Concordance of EUS and MRI/MRCP findings among high-risk individuals undergoing pancreatic cancer screening.

    Siegel A, Friedman M, Feldman D, et al.

    Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.] 2022; (22(7)):951-958 doi:10.1016/j.pan.2022.07.015.

    PMID: 35995658
  11. 11

    Patient experience with endoscopic ultrasound and magnetic resonance cholangiopancreatography for pancreatic cancer screening (The PATRIOT study).

    Silva-Santisteban Merino A, Ariza Manzano KE, Ballou S, et al.

    Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.] 2026; (26(2)):259-264 doi:10.1016/j.pan.2025.12.024.

    PMID: 41571577
  12. 12

    Suboptimal adherence to surveillance in high-risk individuals for pancreatic cancer at a tertiary care academic center: Lessons from real-world surveillance patterns.

    Lee AA, Twoy A, Sutton A, et al.

    Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.] 2025; (25(4)):540-543 doi:10.1016/j.pan.2025.05.002.

    PMID: 40382255
  13. 13

    Assessment of Risk of Hereditary Predisposition in Patients With Melanoma and/or Mesothelioma and Renal Neoplasia.

    Gupta S, Erickson LA, Lohse CM, et al.

    JAMA network open 2021; (4(11)):e2132615 doi:10.1001/jamanetworkopen.2021.32615.

    PMID: 34767027
  14. 14

    BAPoma presenting as an incidental scalp papule: case report, literature review, and screening recommendations for BAP1 tumor predisposition syndrome.

    Zaayman M, Nguyen P, Silfvast-Kaiser A, et al.

    The Journal of dermatological treatment 2022; (33(4)):1855-1860 doi:10.1080/09546634.2021.1939847.

    PMID: 34106034
  15. 15

    Response to "BAP1 Germline Mutation Associated with Bilateral Primary Uveal Melanoma".

    Herwig-Carl MC, Sharma A, Melzer C, et al.

    Ocular oncology and pathology 2021; (7(3)):233-234 doi:10.1159/000513554.

    PMID: 34307337
  16. 16

    BAP1 Germline Mutation Associated with Bilateral Primary Uveal Melanoma.

    Yu MD, Masoomian B, Shields JA, Shields CL

    Ocular oncology and pathology 2020; (6(1)):10-14 doi:10.1159/000499570.

    PMID: 32002398
  17. 17

    GROWTH OF PRESUMED CHOROIDAL NEVUS INTO MELANOMA OVER 4 YEARS IN BAP1 TUMOR PREDISPOSITION SYNDROME.

    Masoomian B, Shields CL, Mashayekhi A, et al.

    Retinal cases & brief reports 2021; (15(2)):93-96 doi:10.1097/ICB.0000000000000772.

    PMID: 29994997
  18. 18

    Updated 2025 French guidelines for renal cell carcinoma.

    Bigot P, Khene ZE, Boissier R, et al.

    The French journal of urology 2025; (35(12)):103007 doi:10.1016/j.fjurol.2025.103007.

    PMID: 41109639
  19. 19

    Advances in pathological diagnosis of mesothelioma: what pulmonologists should know.

    Louw A, Badiei A, Creaney J, et al.

    Current opinion in pulmonary medicine 2019; (25(4)):354-361 doi:10.1097/MCP.0000000000000578.

    PMID: 31169558
  20. 20

    High frequency and unique subtypes of meningioma in patients with BAP1 tumor predisposition syndrome.

    Ramsey KA, Byrne L, Taylor OB, et al.

    Journal of neuro-oncology 2026; (176(3)):207.

    PMID: 41670784
  21. 21

    High Frequency and Unique Subtypes of Meningioma in Patients with BAP1 Tumor Predisposition Syndrome.

    Ramsey KA, Byrne L, Taylor OB, et al.

    medRxiv : the preprint server for health sciences 2025; doi:10.64898/2025.12.04.25341363.

    PMID: 41409666

This page provides educational information on surveillance guidelines for familial melanoma. Always consult your oncology and dermatology teams to create a personalized screening schedule based on your specific genetic risk.

Get notified when new evidence is published on Familial melanoma.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.